Union Health Minister Harsh Vardhan said on Sunday that there is no evidence that could validate claims for the COVID-19 outbreak at multiple focal points globally, with China claiming that coronoviruses broke out in several countries last year .
During a conversation with his social media followers in the sixth episode of “Sunday Samwad”, Mr. Vardhan said that the alleged outbreak of COVID-19 from Wuhan in China has been recognized as the first report worldwide.
In response to a question, he said that China claimed that there was a simultaneous outbreak of the disease in several countries.
“However, to validate the claim that there were multiple focal points around the world, uniform and timely reporting of the occurrence of confirmed and diagnosed cases from different countries is required at the same time. As of now No such evidence is available. Therefore, the alleged outbreak of COVID-19 from Wuhan in China has been recognized as the first report worldwide, “the minister said.
Answering another question in an oximeter-filled market made in China, he said, “Consumers should look for FDA or CE-approved products with ISO or IEC specifications when purchasing pulse oximeters from the market or from online retailers.”
However, he made it clear that a dip in oxygen saturation level is not a COVID-19 symptom, as it may also be caused by other underlying medical conditions.
Mr. Vardhan further stated that so far no mutation of coronavirus has been found in India, which is either more transmission efficient or more pathogenic.
In response to another question, the minister said that although there are no intranasal COVID-19 vaccines currently under trial in the country, Serum Institute of India and Bharat Biotech are expected to undertake clinical trials of such vaccines in the coming months Will be done. regulatory approval.
He clarified that phase-3 clinical trials typically take place with thousands of participants, sometimes close to 30,000 to 40,000. It is possible that from a specific city or hospital, a couple of hundred participants are selected at a given time, but in general, the overall Phase-3 participant pool is much larger.
Sharing the details of the special drive for reporting and monitoring of drugs used in COVID-19, Mr. Vardhan clarified that the drive is not due to an adverse reaction with an existing drug, but is part of an active COVID-19 preparation. Program of